Neurodivergence, together with Consideration Deficit-Hyperactivity Dysfunction (ADHD), stays an space of nice curiosity throughout social media, with excessive ranges of misinformation being unfold on totally different on-line platforms (Carter et al., 2026), as blogged not too long ago by Higson-Sweeney (2026). Regardless of this, there have been no elves running a blog on the therapy of ADHD since our final journey into the woodland earlier this 12 months (Budgen & Suetani, 2026; Zhang et al., 2025).
To not be discouraged, we have now returned to debate an thrilling community meta-analysis from Nourredine et al. (2026). Pharmacological therapy is efficient for ADHD, however particular steering on dosing is proscribed. Generally we don’t know if the dose is simply too little or an excessive amount of. On one hand, there may be concern that clinicians could also be participating in therapeutic inertia – prescribing suboptimal doses the place rising could also be more practical. However, we might threat rising the dose past what’s protected or vital for maximal efficacy. Earlier dose-effect research examined licensed doses in particular age teams and not using a community meta-analysis, which means it was solely doable to discover direct comparability with placebo.
That is the primary dose-effect community meta-analysis throughout age teams for ADHD. The authors examined a broad dataset, together with information past licensed doses, to estimate efficacy and tolerability throughout dosages and age teams. This research makes an attempt to shed some much-needed gentle on the Goldilocks zone – the doses ‘excellent’ for folks with ADHD.
Strategies
Eligible articles have been obtained by means of the MED-ADHD database, a complete repository of double-blind randomised managed trials (RCTs). RCTs with parallel-group or crossover designs utilizing pharmacological monotherapy for at the least 1 week have been included. Individuals have been aged ≥5 with a prognosis of ADHD primarily based on Diagnostic and Statistical Guide of Psychological Issues, Third Version (DSM-III) or later, or equal Worldwide Classification of Ailments (ICD) standards. Notably, research that mixed pharmacotherapy and psychotherapy have been excluded.
Eligible medicines included amphetamines, atomoxetine, bupropion, clonidine, dexmethylphenidate, guanfacine, methylphenidate, modafinil and viloxazine. The dosages for amphetamines have been transformed to dextroamphetamine-equivalents and methylphenidate was transformed to immediate-release methylphenidate hydrochloride primarily based on the conversion components from Farhat et al. (2022). The reported doses are the utmost meant goal dose within the research, not essentially the dose acquired by members.
To evaluate the severity of ADHD signs, the authors extracted ranking scale measures (e.g. SNAP or Conners) and expressed these as a standardised imply distinction (SMD). To evaluate tolerability, the chance of dropout was calculated and expressed as an odds ratio (OR). As a result of this was a Bayesian evaluation, uncertainty is reported as 95% credible intervals (CrI) fairly than confidence intervals: the vary inside which we could be 95% sure the true impact lies.
Outcomes
15,096 references have been discovered on preliminary screening, with 164 research included within the systematic overview and 113 research (68 for youngsters and adolescents and 45 for adults) have been included within the community meta-analysis. There have been a complete of 14,138 kids or adolescents with a imply age of 11 (70.6% male) and 11,016 adults with a imply age of 36 (54.0% male). The principle findings are summarised under:
Kids and Adolescents
Eighteen fixed-dose RCTs with a complete of 4,159 kids or adolescents have been included within the efficacy evaluation. The tolerability evaluation included information from 65 RCTs with a complete of 13,972 people.
- Methylphenidate reached peak efficacy at 45mg/day (SMD −0.89; 95% CrI −1.18 to −0.60).
- Most threat of discontinuation was 2.7% (95% CrI 1.4 to five.1) at 50mg/day. Apparently, rising the dose past the licensed most didn’t increase the discontinuation threat, however precision was low.
- Amphetamines reached peak efficacy at 25mg/day (SMD -1.06; 95% CrI -1.35 to -0.78).
- There was a linear discontinuation threat with the chance exceeding placebo at doses above 25mg/day.
- Lisdexamfetamine was separated with a peak efficacy at roughly 55mg/day (SMD -1.05; 95% CrI -1.4 to -0.69). Based mostly on the conversion components, that is roughly equal to 25mg/day of amphetamines.
- Guanfacine reached peak efficacy at 4mg/day (SMD -0.66; 95% CrI -0.99 to -0.31)
- Discontinuation threat elevated as much as 4mg/day, reaching a median threat of 9.8% (95% CrI 4.4 to twenty). Though the chance appeared to lower following this, with very low certainty.
Inclusion of flexible-dose trials yielded comparable outcomes. These trials included information for dosing at an equal 93mg/day methylphenidate with a prompt decline in efficacy.
Adults
11 fixed-dose RCTs with 2,450 people included within the efficacy evaluation. The tolerability evaluation included information from 42 RCTs with a complete of 10,463 adults.
- Amphetamines reached a plateau at 50mg/day (SMD -0.74; 95% CrI -1.26 to -0.2).
- Notice that the utmost licensed dose by the FDA is 40mg/day
- Threat of discontinuation exceeded placebo (2.6%; 95% CrI 1.8 to three.6) at 50mg/day and continued to extend with dose.
- Methylphenidate efficacy appeared to extend with escalating doses, however there have been marginal positive aspects above roughly 50mg/day.
- Threat of discontinuation exceeded placebo at 50mg/day
- On the most FDA licensed dose of 60mg, the chance of discontinuation elevated to 7.3% (95% CrI 4.3 to 12).
Inclusion of flexible-dose trials expanded the dataset to five,025 adults, and the dose-effect profiles remained unchanged, albeit with narrower credible intervals.
Conclusions
The authors concluded:
Our findings problem each therapeutic inertia — accepting suboptimal response with out additional dose titration — and uncritical dose escalation past licensed limits, when potential harms outweigh anticipated advantages.
Strengths and limitations
There are a lot of strengths on this research on account of its strong design. Most significantly, the inclusion standards have been rigorous within the requirement for double-blind RCT research with prognosis of ADHD primarily based on recognised requirements (DSM & ICD) and a concentrate on fixed-dose trials. This slim definition has resulted in a inhabitants much less reflective of these seen in medical settings. Nevertheless, it’s an acceptable place to begin to scale back the chance of bias and support within the interpretation of outcomes. Whereas many included trials had a excessive threat of bias, sensitivity evaluation excluding these didn’t change the outcomes, supporting the robustness of the findings.
The authors determine a number of limitations with their research and talk about the restricted vary of doses (notably in grownup research), heterogeneous ranking scales for efficacy, lack of capability to conduct subgroup analyses, lack of ability to evaluate the influence of severity, brief length of research and restricted generalisability to medical populations. Particularly, the authors stress that the outcomes from the research are legitimate at a bunch degree, however shouldn’t be used to tell decision-making on the particular person affected person degree on account of variability in response to medicines. We might spotlight the brief durations of the included research (a imply of seven weeks for adults) as a outstanding limitation of this paper. ADHD is a lifelong situation, and many individuals select to proceed pharmacological therapy long-term. Hostile results with long-term use of psychostimulants will not be properly outlined, notably for adults, the place there will likely be rising considerations for cardiovascular unintended effects with longer use at greater doses. These dangers will not be captured within the included research as a result of brief durations.
We additionally stress the constraints as a result of comparatively restricted information for adults. There have been far fewer people within the grownup evaluation compared to kids and adolescents, leading to much less precision within the dose-effect curves, with widening credible intervals at greater doses. Particularly, the amphetamine dose-effect evaluation consisted of information from 459 people, with virtually half (225) receiving a dosage above 40mg/day dextroamphetamine-equivalent. If there have been extra people included within the evaluation, it could be fascinating to see how the dose-effect curves would change and if these would replicate the U-shaped curves seen within the baby and adolescent cohort. The usage of dose conversion to dextroamphetamine-equivalents was vital as a result of restricted dataset; nonetheless, the conversions might have affected the outcomes, as totally different formulations might not have comparable efficacy at these doses. It must also be famous that of the 459 people uncovered to amphetamines, 437 acquired blended amphetamine salts in an extended-release formulation and 22 acquired dextro-amphetamine in a direct launch formulation. No people acquired lisdexamfetamine or dexamfetamine; two medicines generally prescribed in Australia.
Implications for follow
This research builds on the dose-effect responses seen within the meta-analyses by Farhat et al. (2022 & 2024) by means of incorporating oblique proof with the methodology of a community meta-analysis. The outcomes are fascinating and problem frequent medical follow the place prescribers might cease rising dosages when delicate adversarial results are encountered, probably lacking out on peak efficacy. Concurrently, it cautions towards venturing too far into the hazard zone, prescribing greater doses that might not present elevated profit for folks with ADHD. Many medical pointers are likely to assist an individualised strategy of accelerating dosages so long as there may be symptom enchancment and no insupportable adversarial results. This research provides to this by means of discovering that additional will increase past 45mg for methylphenidate and 25mg for amphetamines are unlikely to convey profit and should in actual fact enhance the chance of hurt. For adults, the same dose-dependent enhance in efficacy is seen, reaching a plateau at roughly 50mg for each methylphenidate and amphetamines, with rising dangers past this. Notably, the dose of amphetamines is above the FDA-licensed most dose, probably elevating the notion that doses above these licensed for amphetamines might convey elevated profit on the inhabitants degree.
This research takes a step additional in the direction of a better understanding of efficient dosing within the therapy of ADHD. In beginning to outline the response throughout doses, we’re shifting a lot nearer in the direction of the objective of knowledgeable prescribing and follow. How distant are we from having clear pointers akin to these for antidepressants and antipsychotics with outlined minimal efficient doses and prompt limits above which there’s unlikely to be profit for many sufferers? We now have a wealth of this data for different psychotropic medicines; it’s time that we develop this for ADHD medicines.
At a neighborhood degree, in Australia, it’s tough to know the best way to translate this information into follow, notably for adults. Right here, lisdexamfetamine is the second mostly prescribed psychostimulant (AIHW, 2025). Changing the outcomes from this research, maximal efficacy could also be seen with lisdexamfetamine at roughly 110mg. This dose is much past the 70mg most permitted in most jurisdictions in Australia (AADPA, 2026). Ought to we then be rising the dosage for all adults, so far as tolerated, to the utmost allowed? At this stage, the proof doesn’t assist this follow, given the clear lack of long-term tolerance information in adults and the absence of lisdexamfetamine formulations within the evaluation.
In the end, this research from Nourredine et al. (2026) paves a brand new path in the direction of rising precision with ADHD pharmacological administration and will increase our information of efficient dosing. Additional analysis is now wanted to deal with the gaps in long-term tolerance and to offer extra information throughout a broader vary of medicines and doses. Someday sooner or later, we hope that will probably be simpler to search out the remedy dose ‘excellent’ for folks with ADHD with out the necessity for trial and error like Goldilocks trying to find her porridge.
Assertion of pursuits
Jordan Budgen has no conflicting pursuits with respect to the content material of this weblog publish.
Shuichi Suetani is a member of the Royal Australian and New Zealand Faculty of Psychiatrists ADHD Community, and Australasian ADHD Professionals Affiliation.
Hyperlinks
Main paper
Mikail Nourredine, Lucie Jurek, Tasnim Hamza, Andrea Cipriani, Fabien Subtil, Valeria Parlatini, Luis Farhat, Guilherme Fusetto Veronesi, Orestis Efthimiou, Georgia Salanti, Samuele Cortese (2026) Pharmacological interventions for ADHD: a scientific overview and dose–impact community meta-analysis. The Lancet Psychiatry, 13, 485-495.
Different references
Australasian ADHD Professionals Affiliation (AADPA) (2026). ADHD Medicine Prescribing Laws & Authorities in Australia & New Zealand.
Australian Institute of Well being and Welfare (AIHW) (2025). ADHD Drugs distributed 2004-05 to 2023-24.
Budgen J & Suetani S. Medicine influence on non-core ADHD signs and hurt prevention. The Psychological Elf, 21 Jan 2026.
Farhat L.C., Flores J.M., Behling E. et al. (2022) The consequences of stimulant dose and dosing technique on therapy outcomes in attention-deficit/hyperactivity dysfunction in kids and adolescents: a meta-analysis. Mol Psychiatry 27, 1562–1572.
Farhat, L. C., Flores, J. M., Avila-Quintero, V. J., Polanczyk, G. V., Cipriani, A., Furukawa, T. A., Bloch, M. H., & Cortese, S. (2024). Therapy Outcomes With Licensed and Unlicensed Stimulant Doses for Adults With Consideration-Deficit/Hyperactivity Dysfunction: A Systematic Evaluation and Meta-Evaluation. JAMA psychiatry, 81(2), 157–166.
Higson-Sweeney N. Scrolling for solutions: how dependable is psychological well being and neurodivergence-related data on social media? – Nationwide Elf Service. The Psychological Elf, 22 Apr 2026.
